↓ Skip to main content

Dove Medical Press

Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis

Overview of attention for article published in Drug Design, Development and Therapy, March 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

policy
1 policy source
facebook
1 Facebook page
reddit
1 Redditor

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
138 Mendeley
Title
Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis
Published in
Drug Design, Development and Therapy, March 2013
DOI 10.2147/dddt.s32687
Pubmed ID
Authors

JWL Brown, Alasdair J Coles

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 1%
Ireland 1 <1%
Canada 1 <1%
Brazil 1 <1%
Argentina 1 <1%
Japan 1 <1%
Unknown 131 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 22 16%
Student > Master 21 15%
Researcher 20 14%
Student > Ph. D. Student 16 12%
Student > Postgraduate 13 9%
Other 27 20%
Unknown 19 14%
Readers by discipline Count As %
Medicine and Dentistry 64 46%
Agricultural and Biological Sciences 18 13%
Biochemistry, Genetics and Molecular Biology 5 4%
Neuroscience 5 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 17 12%
Unknown 25 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2016.
All research outputs
#7,960,052
of 25,374,647 outputs
Outputs from Drug Design, Development and Therapy
#543
of 2,268 outputs
Outputs of similar age
#63,865
of 206,322 outputs
Outputs of similar age from Drug Design, Development and Therapy
#9
of 23 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,322 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.